-
Annales de Pathologie Oct 2017
Topics: Breast Neoplasms; Female; Humans; Pathologists; Physician's Role
PubMed: 29037419
DOI: 10.1016/j.annpat.2017.09.001 -
Advances in Anatomic Pathology May 2023Immunotherapy has shown promising results in the treatment of recurrent and metastatic head and neck cancers. Antiprogrammed cell death (PD)-1 therapies have been... (Review)
Review
Immunotherapy has shown promising results in the treatment of recurrent and metastatic head and neck cancers. Antiprogrammed cell death (PD)-1 therapies have been recently approved in this setting and they are currently tested also in the treatment of locally advanced diseases and in the neoadjuvant setting. However, the clinical benefits of these treatments have been quite variable, hence the need to select those patients who may obtain the maximal efficacy through the identification of predictive biomarkers. Currently, PD-L1 immunohistochemical expression by tumor and immune cells is the most widely used predictive biomarker for immunotherapy in head and neck squamous cell carcinoma. Nevertheless, patients with PD-L1 - tumors may still respond to treatments, thereby emphasizing the need for the identification of other predictive biomarkers. In this review, we summarize the current data on histologic and molecular parameters that can be used to select patients with head and neck cancers for immunotherapy, with a focus on squamous cell carcinoma and salivary gland carcinomas.
Topics: Humans; B7-H1 Antigen; Pathologists; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biomarkers
PubMed: 36175939
DOI: 10.1097/PAP.0000000000000374 -
Modern Pathology : An Official Journal... Dec 2023Tumor cell fraction (TCF) estimation is a common clinical task with well-established large interobserver variability. It thus provides an ideal test bed to evaluate...
Tumor cell fraction (TCF) estimation is a common clinical task with well-established large interobserver variability. It thus provides an ideal test bed to evaluate potential impacts of employing a tumor cell fraction computer-aided diagnostic (TCFCAD) tool to support pathologists' evaluation. During a National Slide Seminar event, pathologists (n = 69) were asked to visually estimate TCF in 10 regions of interest (ROIs) from hematoxylin and eosin colorectal cancer images intentionally curated for diverse tissue compositions, cellularity, and stain intensities. Next, they re-evaluated the same ROIs while being provided a TCFCAD-created overlay highlighting predicted tumor vs nontumor cells, together with the corresponding TCF percentage. Participants also reported confidence levels in their assessments using a 5-tier scale, indicating no confidence to high confidence, respectively. The TCF ground truth (GT) was defined by manual cell-counting by experts. When assisted, interobserver variability significantly decreased, showing estimates converging to the GT. This improvement remained even when TCFCAD predictions deviated slightly from the GT. The standard deviation (SD) of the estimated TCF to the GT across ROIs was 9.9% vs 5.8% with TCFCAD (P < .0001). The intraclass correlation coefficient increased from 0.8 to 0.93 (95% CI, 0.65-0.93 vs 0.86-0.98), and pathologists stated feeling more confident when aided (3.67 ± 0.81 vs 4.17 ± 0.82 with the computer-aided diagnostic [CAD] tool). TCFCAD estimation support demonstrated improved scoring accuracy, interpathologist agreement, and scoring confidence. Interestingly, pathologists also expressed more willingness to use such a CAD tool at the end of the survey, highlighting the importance of training/education to increase adoption of CAD systems.
Topics: Humans; Pathologists; Switzerland; Computers
PubMed: 37742926
DOI: 10.1016/j.modpat.2023.100335 -
Fetal and Pediatric Pathology 2024
Topics: Humans; Child; Pathologists; Disasters
PubMed: 38009306
DOI: 10.1080/15513815.2023.2285578 -
The American Journal of Pathology Jan 2022
Topics: Animals; Financing, Organized; Humans; Mice; Mutation; Pathologists; Periodicals as Topic
PubMed: 34762872
DOI: 10.1016/j.ajpath.2021.11.001 -
Der Pathologe Jun 2020
Review
Topics: Emigrants and Immigrants; Germany; History, 20th Century; Humans; Jews; National Socialism; Pathologists; Prejudice
PubMed: 31190235
DOI: 10.1007/s00292-019-0585-4 -
Der Urologe. Ausg. A Jul 2019Besides evidence- and guideline-based tumor therapy, personalized targeted therapies within study settings or individual experimental settings in advanced cancers... (Review)
Review
Besides evidence- and guideline-based tumor therapy, personalized targeted therapies within study settings or individual experimental settings in advanced cancers without further therapeutic options are emerging. A comprehensive molecular analysis of the tumor in a molecular pathology laboratory is important for all targeted therapy approaches. However, the interpretation of the molecular results is crucial and potential therapeutic conclusions can only be drawn by considering the clinical situation and within a setting of oncological experience. Therefore, the molecular results and their potential impact have to be discussed at a molecular tumor board, an interdisciplinary expert team consisting of clinicians, oncologists, (molecular) pathologists, systems physicians, study teams and where required geneticists. If the molecular tumor board decides a targeted therapeutic approach is appropriate, patients should be enrolled in studies or registries with controlled settings and documentation in order to evaluate the therapeutic concepts. Furthermore, molecular-based individual experimental therapies are possible within extreme clinical situations.
Topics: Genetic Testing; Humans; Interdisciplinary Research; Molecular Targeted Therapy; Neoplasms; Pathologists; Pathology, Molecular; Patient Care Team; Precision Medicine; Urologic Neoplasms; Urologists
PubMed: 31049636
DOI: 10.1007/s00120-019-0934-1 -
Pathologica Feb 2022Pediatric liver transplantation represents a safe and long-lasting treatment option for various disease types, requiring the pathologist's input. Indeed, an accurate and... (Review)
Review
Pediatric liver transplantation represents a safe and long-lasting treatment option for various disease types, requiring the pathologist's input. Indeed, an accurate and timely diagnosis is crucial in reporting and grading native liver diseases, evaluating donor liver eligibility and identifying signs of organ injury in the post-transplant follow-up. However, as the procedure is more frequently and widely performed, deceptive and unexplored histopathologic features have emerged with relevant consequences on patient management, particularly when dealing with long-term treatment and weaning of immunosuppression. In this complex and challenging scenario, this review aims to depict the most relevant histopathologic conditions which could be encountered in pediatric liver transplantation. We will tackle the conditions representing the main indications for transplantation in childhood as well as the complications burdening the post-transplant phases, either immunologically ( rejection) or non-immunologically mediated. Lastly, we hope to provide concise, yet significant, suggestions related to innovative pathology techniques in pediatric liver transplantation.
Topics: Child; Humans; Liver Diseases; Liver Transplantation; Living Donors; Pathologists
PubMed: 35212319
DOI: 10.32074/1591-951X-753 -
Annales de Pathologie Apr 2020
Topics: Humans; Neoplasms; Neoplastic Syndromes, Hereditary; Oncogenes; Pathologists
PubMed: 32178890
DOI: 10.1016/j.annpat.2020.02.016 -
Nature Communications Jan 2024Highly multiplexed protein imaging is emerging as a potent technique for analyzing protein distribution within cells and tissues in their native context. However,...
Highly multiplexed protein imaging is emerging as a potent technique for analyzing protein distribution within cells and tissues in their native context. However, existing cell annotation methods utilizing high-plex spatial proteomics data are resource intensive and necessitate iterative expert input, thereby constraining their scalability and practicality for extensive datasets. We introduce MAPS (Machine learning for Analysis of Proteomics in Spatial biology), a machine learning approach facilitating rapid and precise cell type identification with human-level accuracy from spatial proteomics data. Validated on multiple in-house and publicly available MIBI and CODEX datasets, MAPS outperforms current annotation techniques in terms of speed and accuracy, achieving pathologist-level precision even for typically challenging cell types, including tumor cells of immune origin. By democratizing rapidly deployable and scalable machine learning annotation, MAPS holds significant potential to expedite advances in tissue biology and disease comprehension.
Topics: Humans; Pathologists; Machine Learning; Diagnostic Imaging; Proteomics
PubMed: 38167832
DOI: 10.1038/s41467-023-44188-w